A Study of Galcanezumab in Healthy Participants
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 2/28/2019 |
| Start Date: | October 19, 2015 |
| End Date: | January 8, 2018 |
Tolerability, Pharmacokinetics and Pharmacodynamics of LY2951742 in Healthy Subjects Following a Subcutaneous Administration of a Lyophilized Formulation or a Solution Formulation
The purposes of this study are:
- To evaluate tolerability of the Galcanezumab solution injectable formulation (Part A)
- To measure how much of the Galcanezumab lyophilized (freeze dried) injectable
formulation is absorbed into the blood stream and how long it takes the body to get rid
of it compared to the Galcanezumab solution injectable formulation after a single
injection under the skin (subcutaneous [SC]) (Part B).
Information about any side effects that may occur will also be collected. Each part of the
study will last about six months. Participants may only enroll in one part.
- To evaluate tolerability of the Galcanezumab solution injectable formulation (Part A)
- To measure how much of the Galcanezumab lyophilized (freeze dried) injectable
formulation is absorbed into the blood stream and how long it takes the body to get rid
of it compared to the Galcanezumab solution injectable formulation after a single
injection under the skin (subcutaneous [SC]) (Part B).
Information about any side effects that may occur will also be collected. Each part of the
study will last about six months. Participants may only enroll in one part.
Inclusion Criteria:
- Male and female healthy participants
- Have a body mass index of 19.0 to 35.0 kilograms per meter square (kg/m²), inclusive
Exclusion Criteria:
- Currently smoke in excess of 5 cigarettes/day
We found this trial at
1
site
Click here to add this to my saved trials
